Form D · Pharmaceuticals
Vyripharm Enterprises, Inc.
Houston, TX · CIK 0001887609
Offering snapshot reported Oct 28, 2021 · SEC filing
- Reported sold
- $300M Offering amount: $300M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 13, 2021 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 28, 2021 | Initial | $300,000,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-418970
Source: Form D, filed Oct 28, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jerry Bryant | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
2450 Holcombe Blvd Suite Xi I.218
Houston, TX, 77021
Houston, TX, 77021